Recently, Immix Biopharma - an international privately-held cancer research biopharmaceutical firm - developed IMX-110. A first-in-class combination therapy, IMX-110 is a cancer resistance inhibitor. However, rather than directly kill cancer cells (and cause collateral damage to healthy normal cells) Immix's combination reactivates programmed cell death (apoptosis) that naturally occurs in cancer cells, which leads to their death. IMX-110 has demonstrated pre-clinical efficacy for various cancers - including triple-negative breast, ovarian, colorectal, pancreatic tumor, and multiple myeloma and more recently for various forms of sarcoma.
A combination of NF-kB/Stat3/pan-kinase inhibitor curcumin and a trace amount of doxorubicin packed in a nano-sized delivery system allows the drug to carry out optimal tumor penetration. IMX-110 binds well with specific target molecules and delivers a sufficient concentration of active chemicals to target key areas in cells. Compared to doxorubicin alone, IMX-110 is five times as efficient in inducing cancer cell apoptosis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.